Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MEDI3506 in adults with uncontrolled moderate-to-severe asthma
2020-000789-40Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing MEDI3506 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 16 in pre-bronchodilator FEV1. Started Jul 2020; status: completed.
02
Drugs
tozorakimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2020-000789-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000789-40.